• Sep 8, 2020

  Immunic, Inc. to Participate in Scientific and Investor Conferences in September
• Aug 20, 2020

  Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
• Aug 10, 2020

  Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
• Aug 4, 2020

  Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
• Aug 3, 2020

  Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock